Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

ADMA Biologics Securities Fraud Class Action

ADMA Biologics · ASCENIV immune globulin solution · Ongoing Litigation

About this case

The putative securities class action alleges that ADMA Biologics and certain executives made false or misleading statements or failed to disclose an undisclosed related-party transaction, channel stuffing, and inadequate internal controls, allegedly causing losses to investors who purchased the company’s publicly traded securities. The action is ongoing, and the lead-plaintiff application deadline was August 10, 2026.

Case overview

Defendant company
ADMA Biologics
Product or service
ASCENIV immune globulin solution
Case name
Mazzarino v. ADMA Biologics, Inc., et al.
Court case number
No. 26-cv-6918
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead Plaintiff Application
ADMA Biologics Lead Plaintiff Application
Schall Law Firm investor case inquiry

Participation information

Lead Plaintiff Application

Investors who purchased ADMA Biologics shares during the class period of August 9, 2024 through March 25, 2026 may have been eligible to seek appointment as lead plaintiff.

Contact DJS Law Group regarding a possible lead-plaintiff appointment.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear

ADMA Biologics Lead Plaintiff Application

Investors who purchased or acquired ADMA Biologics publicly traded securities between August 9, 2024 and March 25, 2026, inclusive, could seek appointment as lead plaintiff.

Submit information through the Robbins Geller intake page or contact the firm. The lead-plaintiff application deadline was August 10, 2026.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Apply as lead plaintiff Apply as lead plaintiff

Schall Law Firm investor case inquiry

Investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026, inclusive, and suffered a loss were encouraged to contact the Schall Law Firm.

Contact Brian Schall or the Schall Law Firm to discuss potential rights and participation in the case.

Type
Law Firm Signup
Status
Deadline passed
Reported proof requirement
Unclear

Lead Plaintiff Opportunity

Investors who purchased ADMA Biologics shares during the applicable class period may contact the law firm regarding a possible lead-plaintiff appointment.

Contact Schall, Brown & Schwartz LLP regarding a possible lead-plaintiff appointment.

Type
Lead Plaintiff

Sources